• Mashup Score: 0

    September 7, 2023 — Vektor Medical, developer of the only technology to accurately map arrhythmias using just 12-lead ECG data, has announced the release of a series of software enhancements to its AI-based non-invasive solution, vMap. Designed to improve ablation outcomes and procedural efficiencies, the newly updated vMap software integrates additional automation and advanced visualization features. vMap is the only FDA-cleared, AI-based non-invasive solution that unlocks the data contained in a standard 12-lead ECG, enabling physicians to rapidly and accurately locate arrhythmia source locations. According to a statement issued by the San Diego, CA-based company, the software upgrades are designed to improve the accuracy, visualization, and efficiency of arrhythmia analysis and interpretation. The updates include: – Beat Assist: Software recommends and auto-selects arrhythmic beats of interest that may indicate the source location of an arrhythmia. This new functionality reduces unc

    Tweet Tweets with this article
    • @DAICeditor @VektorMedical The newly updated #vMap #software integrates additional automation and advanced visualization features, and is designed to improve #ablation outcomes and procedural efficiencies: https://t.co/a9wCwvVLtn

  • Mashup Score: 0

    August 31, 2023 — Atrial fibrillation ablation is associated with lower rates of death, urgent heart transplantation or left ventricular assist device (LVAD) implantation compared with medical therapy in patients with end-stage heart failure, according to late breaking research presented in a Hot Line session today at ESC Congress 2023.1  Patients with end-stage heart failure eligible for heart transplantation have been excluded from major trials, leaving them with no recommendations or evidence for the optimal treatment of atrial fibrillation and advanced heart failure. There is uncertainty around the application of guidelines in this group2,3 and many novel advances in heart failure therapy are withheld in clinical practice.  The CASTLE-HTx trial tested whether atrial fibrillation ablation is superior to medical therapy concerning mortality and need for urgent transplantation or LVAD implantation.4 The trial was conducted at the Heart and Diabetes Center North Rhine-Westphalia (NRW)

    Tweet Tweets with this article
    • @DAICeditor @escardio #Atrialfibrillation #ablation is associated with lower rates of death, urgent #hearttransplantation, left ventricular assist device implantation compared with #medicaltherapy in patients with end-stage #heartfailure: https://t.co/BfnDLf6AnS #ESC23 #esc2023

  • Mashup Score: 0

    In adults with paroxysmal atrial fibrillation, pulsed field ablation was noninferior to conventional thermal ablation for safety and efficacy, with significantly less pulmonary vein narrowing and faster procedure times, researchers stated.Thermal ablation, whether via radiofrequency (heat) or cryoballoon methods, is highly effective for treating paroxysmal AF; however, the ablative energy is

    Tweet Tweets with this article
    • Pulsed field #ablation for paroxysmal #AFib was noninferior to conventional thermal ablation for safety and efficacy, with less pulmonary vein narrowing and faster procedure times @VivekReddyMD @MountSinaiHeart #ESCCongress @ESCardioNews #cardiotwitter https://t.co/n9vWzcvpZE

  • Mashup Score: 3

    Vasovagal syncope (VVS) is a clinical condition caused by sudden-onset bradycardia (cardioinhibitory response) and hypotension (vasodepressor response).1 Howeve

    Tweet Tweets with this article
    • Pacing or ablation for vasovagal syncope? Read the practical decision pathway for managing vasovagal syncope in #EHJ. https://t.co/cwPYJh3rL6 #pacing #ablation #syncope @MDTolgaAksu @CarlChiefCard #cardiotwitter @ESC_Journals @escardio https://t.co/G86D7E6WSt